Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Oncology Advance of the Year – Innovations in Surgical Treatment Selected

Oncology Advance of the Year – Innovations in Surgical Treatment Selected

Oncological surgery improvements were named in the annual report of the American Society of Clinical Oncology (ASCO) as the clinical cancer advance of the year . The report states that recent successes with more effective cancer treatments have changed the role of cancer surgery, reducing its need in melanoma, pancreatic, kidney, and bladder cancers. Surgery plays a fundamental role in cancer treatment and was the only available option for hundreds of years. The explosion of systemic therapies since the 1950s has significantly changed when and how surgery is performed to treat cancer. ASCO's annual report on progress against cancer, published for its 15th year, appeared on February 4 in the Journal of Clinical Oncology online. Clinical Cancer Advances 2020 lists numerous clinical advances in cancer treatment from October 2018 through September 2019, but highlights the following studies as “some of this year's most impressive research achievements” . These studies provide new insights into how systemic therapies reduce the amount of surgery needed, sometimes eliminate the need altogether, and can make patients eligible for surgery when necessary.

Neoadjuvant (Preoperative Tumor-Shrinking) Treatments in Melanoma

Two clinical trials demonstrate how targeted drugs and immunotherapy agents allow successful and less minimal surgery for patients with locally advanced melanoma. Lancet Oncologypublished the NeoCombi study investigating neoadjuvant dabrafenib (Tafinlar) plus trametinib (Mekinist) in stage IIIC melanoma with a BRAF V600 mutation. Among 35 participants, % 86 had an objective response at surgery, and nearly half (% 46) had a complete response . The two-drug combination facilitated surgical removal of the tumor and surrounding tissue in % 46 of patients. Adverse effects were generally similar to those previously reported among patients receiving these treatments for metastatic disease. Also, Lancet Oncologypublished OpACIN-neo, studying two immunotherapies, ipilimumab (Yervoy) and nivolumab (Opdivo), in resectable stage III melanoma. Patients receiving 2 cycles of an alternative dose (every 3 weeks, ipilimumab 1 mg/kg and 3 mg/kg nivolumab) had a radiological objective response rate of % 57 and a pathological response rate of % 77. Fewer severe adverse effects were also reported during the first 12 weeks (grade 3/4), compared with standard dosing (for 4 cycles every 3 weeks, ipilimumab 3 mg/kg plus nivolumab 1 mg/kg). These data suggest reducing ipilimumab and nivolumab doses in this approach may improve tolerability, but long-term results are needed before recommending it as standard care.

Eliminating the “Surgery First” Approach in Kidney Cancer

Surgery has traditionally been the primary treatment for many solid tumors, including kidney cancer, renal cell carcinoma, but results of two recently published studies suggest that for some patients, skipping surgery is better . NEJMpublished CARMENA results showing that “sunitinib (Sutent) alone” had outcomes similar to “nephrectomy surgery plus sunitinib” in metastatic kidney cancer in 450 patients. Median overall survival was 18.4 months with sunitinib alone and 13.9 months with surgery plus sunitinib. Median overall survival with sunitinib was also longer in patients classified as having poor and intermediate survival prospects (respectively 23.4 versus 19.0 months and 13.3 versus 10.2 months). Grade 3 or higher adverse effects were slightly higher with sunitinib alone (% 42.7 versus% 32). JAMA Oncologypublished SURTIME results showing that a surgery-first approach did not improve progression-free survival compared with giving sunitinib before surgery. In clear cell disease, the most common kidney cancer subtype, and stage 4 , a group of 99 patients had similar progression-free survival outcomes between arms at week 28 (% 42 versus % 43). However, median overall survival with sunitinib and deferred surgery was 32.4 months, compared with 15 months after immediate surgery.

Making Surgery Possible for Pancreatic Cancer

The best survival outcomes in pancreatic cancer are achieved with surgery, but patients are often diagnosed at advanced stages when surgical tumor removal is not possible. Two studies suggest that preoperative systemic treatment may allow some patients to undergo surgery. JAMA Oncologypublished a single-arm phase 2 trial evaluating neoadjuvant FOLFIRINOX plus radiotherapy in borderline resectable pancreatic cancer in 48 patients. Patients were restaged after treatment. Those whose vascular involvement, cancer spread to vessels, resolved received short-course proton radiotherapy with capecitabine. Those with persistent vascular involvement received standard radiotherapy plus capecitabine or fluorouracil. Median progression-free survival for the full group was 14.7 months and overall survival 37.7 months. Among the 31 operated patients, % 67 could achieve negative surgical margins; progression-free survival improved significantly in this group (48.6 months). Median overall survival had not yet been reached because more than half remained alive, but at year 2 overall survival was % 72 in the operable group and % 56 among all patients. Also, JAMA Oncologypublished a second single-arm phase 2 study evaluating FOLFIRINOX plus the blood pressure drug acting on the renin–angiotensin–aldosterone system, losartan , in locally advanced pancreatic cancer. Patients becoming radiologically operable after treatment also received short-course proton radiotherapy and capecitabine; patients with persistent vascular involvement received standard long-course radiotherapy with fluorouracil or capecitabine. Results showed that % 61 underwent surgery with negative margins. Median progression-free survival for the whole group was 17.5 months and overall survival 31.4 months. Among operable patients, median progression-free survival was 21.3 months and overall survival 33 months.

Conclusion

Some of the past year's most impressive cancer research achievements concerned oncological surgery. While the need for initial surgery in advanced kidney cancer was eliminated, we saw that adding effective systemic therapies and modern radiotherapy combinations to surgery improved disease outcomes in melanoma and pancreatic cancer.

Sources

Refinement of Surgical Treatment' Is ASCO Advance of the Year - Medscape - Feb 12, 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Oncology Advance of the Year – Innovations in Surgical Treatment Selected

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy